Attenuated salmonella enterica serovar paratyphi a and uses thereof

US20120029173A1Active Publication Date: 2012-02-02MARYLAND UNIV OF
3 Cites 1 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
Publication Date
2012-02-02

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention is drawn to a live, attenuated S. Paratyphi A strain, a live, attenuated S. Paratyphi A strain comprising a stabilized plasmid expression system, an S. Paratyphi conjugate vaccine, and methods of using these strains and conjugate vaccine.
Need to check novelty before this filing date? Find Prior Art

Description

RELATED APPLICATIONS

[0001] The present application is a continuation-in-part of U.S. patent application Ser. No. 12 / 091,929, filed Apr. 28, 2008, which claims the benefit of International Application No. PCT / US06 / 42148, filed Oct. 30, 2006, and the benefit of U.S. Provisional Application No. 60 / 731,349, filed Oct. 28, 2005. The entire disclosure and teachings of the above-referenced Applications are incorporated herein by reference.STATEMENT OF FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

[0002] This invention was made with government support under NIH Grant No. A1029471 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND OF THE INVENTION

[0003] Enteric fever caused by members of the genus Salmonella, including typhoid and paratyphoid fevers, continues to constitute a significant disease and mortality burden among populations in developing countries (Lancet 2005; 366:749-762) and represents a notable risk for travelers (Lancet Infec...

Examples

Embodiment Construction

A. Attenuated S. Paratyphi A Strains

[0036]The present invention relates to an attenuated S. Paratyphi A strain. Such attenuated S. Paratyphi A strains may be used to induce an immune response in a subject without causing disease in the subject.

[0037]The S. Paratyphi A strain used as the starting material of the present invention may be any S. Paratyphi A strain and the identity of the strain is not critical. Preferred S. Paratyphi A strains include S. Paratyphi A 9150 strain.

[0038]The S. Paratyphi A strains of the present invention are attenuated. As used herein, attenuated strains of S. Paratyphi A are those that have a reduced, decreased, or suppressed ability to cause disease in a subject, or those completely lacking in the ability to cause disease in a subject. Attenuated strains may exhibit reduced or no expression of one or more genes, may express one or more proteins with reduced or no activity, may exhibit a reduced ability to grow and divide, or a combination of two or more...